DRonabinol Treatment of OSA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-25

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Helping Olfaction and Nutrition On Renal Replacement

NCT02479451

End Stage Renal Disease Olfactory Disorders

COMPLETED PHASE2

Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate

NCT02135965

Healthy Volunteers

COMPLETED EARLY_PHASE1

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

NCT00977171

Chronic Fatigue Syndrome Orthostatic Hypotension Neurally Mediated Hypotension +1 more

TERMINATED PHASE2

Investigating the Effects of Nabilone on Endocannabinoid Metabolism

NCT05885685

Healthy

RECRUITING PHASE4

The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial

NCT02115763

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.

This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

120 Veterans will be screened and enrolled to achieve 45 participants completing the study. All participants will receive oral Dronabinol treatment nightly for two weeks.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single group

Open label Dronabinol treatment for two weeks.

Group Type EXPERIMENTAL

Dronabinol

Intervention Type DRUG

Open label Dronabinol treatment for two weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dronabinol

Open label Dronabinol treatment for two weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Marinol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults 18 to 65 years of age.
2. AHI 15-50 per hour on pre-treatment polysomnography.

Exclusion Criteria

1. Positive Airway Pressure (PAP) treatment of OSA: use \> 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data.
2. Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use \> 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report.
3. History of upper airway surgery for OSA (except adenotonsillectomy).
4. Central or mixed apneas \>25% of respiratory events on diagnostic polysomnography.
5. Arterial oxygen saturation \< 75% for \> 5% sleep time on pretreatment polysomnography.
6. Body mass index \> 45 kg/m2.
7. If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug.
8. Active enrollment in a weight loss program.
9. Shiftwork within 3 months of enrollment.
10. High-risk occupation: commercial driver and pilot.
11. Motor vehicle accident or near-miss incident within 1 year of enrollment.
12. Current drug or habitual alcohol use or positive urine drug screen.
13. Comorbid medical and psychiatric disorders:

1. Primary sleep disorders: e.g., narcolepsy, restless legs syndrome.
2. Uncontrolled mood disorder or a diagnosis of schizophrenia.
3. Initiation of new antidepressant or antipsychotic medication within 3 months.
4. Identified as high-risk for suicide in electronic health records.
5. Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders).
14. Use of sedative-hypnotic medications within 30 days of enrollment.
15. Complete blood count or liver function test values more than 1.5 times the upper limit of normal.
16. Pregnancy.
17. Allergy to cannabinoids or sesame oil.
18. Average weekly alcohol consumption of more than 10 servings.
19. Participation in other investigational protocols within 30 days of enrollment.

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No